Whitehawk Therapeutics, Inc.
WHWK
$4.16
$0.051.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -- | -- | 33.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -- | -- | 33.48% |
| Cost of Revenue | 80.48% | 25.66% | 32.81% | 251.88% | -32.97% |
| Gross Profit | -617.10% | -140.83% | -299.69% | -534.54% | 72.98% |
| SG&A Expenses | -50.92% | -46.92% | -27.62% | -24.73% | 20.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.18% | -4.97% | 8.67% | 151.57% | -10.06% |
| Operating Income | -54.57% | -31.34% | -81.40% | -251.32% | 22.01% |
| Income Before Tax | -130.40% | -27.24% | -41.45% | -260.80% | 499.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -130.40% | -27.24% | -41.45% | -260.80% | 499.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -130.40% | -27.24% | -41.45% | -260.80% | 499.23% |
| EBIT | -54.57% | -31.34% | -81.40% | -251.32% | 22.01% |
| EBITDA | -55.14% | -31.66% | -82.15% | -252.32% | 22.10% |
| EPS Basic | -117.41% | 50.21% | 44.74% | -41.06% | 371.71% |
| Normalized Basic EPS | 11.96% | 50.19% | 30.70% | -41.08% | 46.31% |
| EPS Diluted | -117.52% | 50.32% | 43.97% | -41.04% | 369.12% |
| Normalized Diluted EPS | 11.29% | 50.19% | 30.70% | -41.08% | 46.71% |
| Average Basic Shares Outstanding | 74.66% | 155.52% | 155.92% | 155.77% | 46.92% |
| Average Diluted Shares Outstanding | 73.38% | 155.52% | 155.92% | 155.77% | 48.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |